CurisCRIS
About: Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Employees: 49
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
5.52% less ownership
Funds ownership: 39.15% [Q2] → 33.62% (-5.52%) [Q3]
9% less funds holding
Funds holding: 34 [Q2] → 31 (-3) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
32% less capital invested
Capital invested by funds: $15.9M [Q2] → $10.8M (-$5.07M) [Q3]
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Edward White 28% 1-year accuracy 31 / 112 met price target | 428%upside $20 | Buy Reiterated | 15 Nov 2024 |
HC Wainwright & Co. Edward White 28% 1-year accuracy 31 / 112 met price target | 428%upside $20 | Buy Maintained | 1 Nov 2024 |
HC Wainwright & Co. Edward White 28% 1-year accuracy 31 / 112 met price target | 586%upside $26 | Buy Reiterated | 27 Sept 2024 |
Financial journalist opinion
Based on 5 articles about CRIS published over the past 30 days
